Cue Biopharma (NASDAQ:CUE) PT Lowered to $3.00 at Piper Sandler

Cue Biopharma (NASDAQ:CUE) had its price objective decreased by Piper Sandler from $8.00 to $3.00 in a research note issued to investors on Friday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other equities analysts also recently issued reports on the company. Oppenheimer reiterated an outperform rating and issued a $10.00 price objective on shares of Cue Biopharma in a research report on Tuesday, April 9th. Stifel Nicolaus reaffirmed a buy rating and issued a $8.00 target price on shares of Cue Biopharma in a research note on Tuesday, April 9th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of Buy and a consensus target price of $5.80.

Cue Biopharma Stock Performance

Shares of NASDAQ CUE opened at $0.65 on Friday. Cue Biopharma has a 12 month low of $0.62 and a 12 month high of $3.90. The business’s 50 day moving average is $1.25 and its two-hundred day moving average is $1.78. The company has a market cap of $31.46 million, a P/E ratio of -0.61 and a beta of 1.96. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.11.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.05. The business had revenue of $1.72 million for the quarter, compared to analysts’ expectations of $0.73 million. Cue Biopharma had a negative return on equity of 128.30% and a negative net margin of 711.84%. On average, equities analysts expect that Cue Biopharma will post -0.97 EPS for the current year.

Institutional Trading of Cue Biopharma

A number of institutional investors have recently modified their holdings of the company. Wedmont Private Capital raised its holdings in Cue Biopharma by 100.0% during the first quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock worth $76,000 after acquiring an additional 20,000 shares in the last quarter. Navalign LLC acquired a new stake in Cue Biopharma during the 4th quarter valued at $66,000. Legacy Capital Group California Inc. bought a new stake in shares of Cue Biopharma during the 4th quarter worth about $26,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Cue Biopharma by 7.1% during the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after acquiring an additional 150,457 shares during the period. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.